Neurocrine Non Current Liabilities Other from 2010 to 2024

NBIX Stock  USD 136.91  0.08  0.06%   
Neurocrine Biosciences Non Current Liabilities Other yearly trend continues to be fairly stable with very little volatility. Non Current Liabilities Other will likely drop to about 9.8 M in 2024. During the period from 2010 to 2024, Neurocrine Biosciences Non Current Liabilities Other regression line of annual values had r-squared of  0.22 and arithmetic mean of  29,865,600. View All Fundamentals
 
Non Current Liabilities Other  
First Reported
2011-06-30
Previous Quarter
30.1 M
Current Value
100 K
Quarterly Volatility
48.9 M
 
Yuan Drop
 
Covid
Check Neurocrine Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Neurocrine Biosciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 22.4 M, Interest Expense of 7.4 M or Selling General Administrative of 894.2 M, as well as many indicators such as Price To Sales Ratio of 6.48, Dividend Yield of 0.0 or PTB Ratio of 6.13. Neurocrine financial statements analysis is a perfect complement when working with Neurocrine Biosciences Valuation or Volatility modules.
  
Check out the analysis of Neurocrine Biosciences Correlation against competitors.
For more information on how to buy Neurocrine Stock please use our How to Invest in Neurocrine Biosciences guide.

Latest Neurocrine Biosciences' Non Current Liabilities Other Growth Pattern

Below is the plot of the Non Current Liabilities Other of Neurocrine Biosciences over the last few years. It is Neurocrine Biosciences' Non Current Liabilities Other historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Neurocrine Biosciences' overall financial position and show how it may be relating to other accounts over time.
Non Current Liabilities Other10 Years Trend
Slightly volatile
   Non Current Liabilities Other   
       Timeline  

Neurocrine Non Current Liabilities Other Regression Statistics

Arithmetic Mean29,865,600
Geometric Mean9,480,884
Coefficient Of Variation141.27
Mean Deviation32,229,947
Median9,785,000
Standard Deviation42,190,140
Sample Variance1780T
Range116.9M
R-Value0.47
Mean Square Error1497.8T
R-Squared0.22
Significance0.08
Slope4,411,068
Total Sum of Squares24920.1T

Neurocrine Non Current Liabilities Other History

20249.8 M
202310.3 M
202229.7 M
2021117.6 M
2020104.1 M
2019103.8 M
201835.7 M

About Neurocrine Biosciences Financial Statements

Neurocrine Biosciences investors use historical fundamental indicators, such as Neurocrine Biosciences' Non Current Liabilities Other, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Neurocrine Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Non Current Liabilities Other10.3 M9.8 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Neurocrine Stock Analysis

When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.